West Virginia PEIA cancels its 1,000-person GLP-1 obesity pilot

West Virginia's Public Employees Insurance Agency (PEIA) paused a five-year pilot program on March 15, 2024, that had covered GLP-1 medications for obesity treatment, citing a monthly cost of about $1.3 million even after manufacturer rebates ^[1][2]. The program had covered a little over 1,000 patients since it began in 2019 ^[1].

PEIA provides health coverage to more than 230,000 public employees and retirees in a state with the nation's highest adult obesity rate, at 41.6 percent, according to 2024 data from the Centers for Disease Control and Prevention ^[1]. State officials told local media the decision was "multifaceted," pointing to cost, drug supply shortages, potential side effects, and what they called inconclusive results ^[1].

The financial pressure was significant. Sen. Tom Takubo, who chairs the legislature's Joint Standing Committee on Insurance and PEIA, said spending on this class of medication had climbed to about $90 million and "completely breaks the bank" ^[1]. PEIA honored existing prior authorizations through June 30, 2024, or the length of the authorization, whichever was longer ^[1].

West Virginia was not alone. Colorado ended similar coverage for its state employee health plan effective July 1, 2025, expecting to save $17 million a year ^[2]. North Carolina's state health plan, which had covered these drugs since 2015, pulled back coverage in January 2024 after utilization rose 731 percent to more than 23,000 members, with projected costs exceeding $170 million in 2024 and more than $1 billion over six years ^[2]. As of March 2025, only 11 states covered GLP-1s for weight loss under state employee health plans, and only five states covered them under both a state employee plan and Medicaid ^[2].

List prices for these drugs remain a central driver of the cost. Novo Nordisk lists Ozempic at $968.52 per month before insurance or discounts, based on four weekly doses ^[1].

Why it matters for patients

For West Virginia state employees who relied on the pilot, the end of coverage means paying list price or losing access to the medication altogether unless they qualify under a different diagnosis, such as diabetes or a heart condition covered by Medicare in some cases ^[1]. One patient in the program, Cassie Maxwell of Morgantown, said she lost nearly 150 pounds and saw her blood pressure, cholesterol, and sleep apnea improve while covered, but was told her health markers would need to worsen before coverage might return ^[1].

The cancellation illustrates a broader tension facing patients nationwide: state and employer health plans are weighing the immediate cost of GLP-1 drugs against the uncertain, longer-term savings from preventing obesity-related disease. Advocates like Laura Davisson, director of Medical Weight Management at West Virginia University, argue the state will end up paying for obesity-related illness anyway, citing data showing patients in the pilot who continued treatment saw a 15.4 percent decrease in body mass index ^[1]. State budget officials, however, must weigh those projected benefits against costs that are certain and immediate.

Patients on employer or state coverage elsewhere should not assume their own plan's GLP-1 policy is stable, since multiple states have reversed course on coverage within just a year or two of adopting it ^[2].

What happens next

Two bills aimed at restoring or mandating PEIA coverage of GLP-1s, House Bill 4979 and House Bill 116, stalled in West Virginia legislative committees during 2024 and did not advance ^[1]. Takubo said lawmakers were working "behind the scenes" with drug manufacturers on possible qualifying criteria for future coverage, though no timeline or details have been announced ^[1]. As of March 2025, only Arkansas, California, Maryland, New Mexico, Pennsylvania, and Texas had introduced bills mandating GLP-1 coverage that year, and none were expected to advance ^[2].